IBD frequently coexists with SpA, and sulfasalazine reduces or eliminates symptoms of both conditions in many of these patients. Prior studies have suggested that it works via the gut microbiome ...

Hong Kong-based Insilico Medicine said its generative artificial intelligence (AI) platforms helped it design a molecule that ...

The IBD category overall is becoming increasingly ... Analysts at GlobalData have predicted that, fuelled by new indications, the two drugs could make peak combined sales of $32 billion by 2020 ...

New Delhi: Inflammatory Bowel Disease (IBD) is a chronic condition characterized by recurring inflammation of the ... Praveen ...

Inflammatory bowel disease (IBD) affects an estimated 1.6 million Americans. In fact, there are more than 70,000 new cases of ...

Yet, there is not going to be an new IBD treatment imminently. The researchers have a head start as drugs already exist, but they need to find a way of targeting just the macrophages so they do ...

Hmm, except for software, the growth groups are missing from the "new highs" list this weekend in @IBDinvestorspaper. Consistent with the weakness in growth stocks ...

Early intervention is key One of the major problems with IBD is that the disease can progress in your body for a long time without manifest symptoms, allowing damage to the gastrointestinal tract to ...

This is thought to keep the inflammation from IBD in check. However, this also means that the body is less able to fight off infections, such as those that are caused by bacteria or viruses, including ...